However, in the IMvigor210 cohort of patients with urothelial carcinoma treated with the anti-PD-L1 antibody atezolizumab, the response rates to immunotherapy were almost identical in the Risk-H and Risk-L groups (Fig. 4D). The gene discussed is CD274; the disease is urothelial carcinoma.